Low-dose aspirin of heart help only in some diabetics

May 16, 2011

Article

NEW YORK (Reuters Health) - Low-dose aspirin is predominantly of value in reducing atherosclerotic events in patients with less advanced diabetes, Japanese researchers report in an April 22nd online paper in Diabetes Care.

Recent Videos

1 expert is featured in this series.

1 expert is featured in this series.

Related Content

Q&A: What AI Is, How It’s Helping Pharmacies with Compliance | NCPDP 2025

Q&A: What AI Is, How It’s Helping Pharmacies with Compliance | NCPDP 2025

Brian Nowosielski;Stanley V. Campbell, Jr;Yi Deng, PhD

Stanley V. Campbell, Jr., CEO of EagleForce Associates, Inc., and Yi Deng, PhD, Senior Vice President of Engineering at EagleForce, discuss the basics of AI and how it’s assisting with compliance.

Demystifying PBMs, Their Role in the Drug Supply Chain

Demystifying PBMs, Their Role in the Drug Supply Chain

Brian Nowosielski;Antonio Ciaccia

President of 3 Axis Advisors and CEO of 46brooklyn Research joins Drug Topics to discuss nuances surrounding pharmacy benefit managers and the way they are perceived in the public eye.

Roflumilast Foam Improves Symptoms of Scalp, Body Psoriasis

Roflumilast Foam Improves Symptoms of Scalp, Body Psoriasis

The therapy is currently under FDA review and has a PDUFA action date of May 22, 2025.

Scripted for Her: Helping Patients Choose Contraceptive Methods

Scripted for Her: Helping Patients Choose Contraceptive Methods

Killian Meara;Natalie DiPietro Mager, PharmD, PhD;Jasmine Cutler, PharmD, CPh

In this episode of the podcast, Natalie DiPietro Mager, PharmD, PhD, sits down with Jasmine Cutler, PharmD, CPh.

Tremfya Demonstrates Sustained Response Up to 92 Weeks

Tremfya Demonstrates Sustained Response Up to 92 Weeks

Ashley Gallagher

Guselkumab is the first and only IL-23 inhibitor to demonstrate robust data as a fully subcutaneous regimen.

Calories to Satiation Predicts Patients Likely to Experience Adverse Events From GLP-1s

Calories to Satiation Predicts Patients Likely to Experience Adverse Events From GLP-1s

Ashley Gallagher

Patients often have anxiety about potential adverse effects, and experiencing adverse effects can affect patient adherence.

Related Content

Q&A: What AI Is, How It’s Helping Pharmacies with Compliance | NCPDP 2025

Q&A: What AI Is, How It’s Helping Pharmacies with Compliance | NCPDP 2025

Brian Nowosielski;Stanley V. Campbell, Jr;Yi Deng, PhD

Stanley V. Campbell, Jr., CEO of EagleForce Associates, Inc., and Yi Deng, PhD, Senior Vice President of Engineering at EagleForce, discuss the basics of AI and how it’s assisting with compliance.

Demystifying PBMs, Their Role in the Drug Supply Chain

Demystifying PBMs, Their Role in the Drug Supply Chain

Brian Nowosielski;Antonio Ciaccia

President of 3 Axis Advisors and CEO of 46brooklyn Research joins Drug Topics to discuss nuances surrounding pharmacy benefit managers and the way they are perceived in the public eye.

Roflumilast Foam Improves Symptoms of Scalp, Body Psoriasis

Roflumilast Foam Improves Symptoms of Scalp, Body Psoriasis

The therapy is currently under FDA review and has a PDUFA action date of May 22, 2025.

Scripted for Her: Helping Patients Choose Contraceptive Methods

Scripted for Her: Helping Patients Choose Contraceptive Methods

Killian Meara;Natalie DiPietro Mager, PharmD, PhD;Jasmine Cutler, PharmD, CPh

In this episode of the podcast, Natalie DiPietro Mager, PharmD, PhD, sits down with Jasmine Cutler, PharmD, CPh.

Tremfya Demonstrates Sustained Response Up to 92 Weeks

Tremfya Demonstrates Sustained Response Up to 92 Weeks

Ashley Gallagher

Guselkumab is the first and only IL-23 inhibitor to demonstrate robust data as a fully subcutaneous regimen.

Calories to Satiation Predicts Patients Likely to Experience Adverse Events From GLP-1s

Calories to Satiation Predicts Patients Likely to Experience Adverse Events From GLP-1s

Ashley Gallagher

Patients often have anxiety about potential adverse effects, and experiencing adverse effects can affect patient adherence.

Editorial Board

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.